Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Pigment Cell & Melanoma Research|August 25, 2015
MITF is a critical regulator of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in malignant melanomaNico Ullrich, Stefanie Löffek, Susanne Horn, et al.
The Journal of Investigative Dermatology|June 24, 2019
Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma CellsFelix C E Vogel, Natalie Bordag, Elmar Zügner, et al.
Cancers|February 13, 2021
Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant MelanomaRenáta Váraljai, Susanne Horn, Antje Sucker, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|February 20, 2024
The adhesion GPCR and PCP component flamingo (FMI-1) alters body size and regulates the composition of the extracellular matrixJohanna Lena Schön, Victoria Elisabeth Groß, Willem Berend Post, et al.
BMC Genomics|November 8, 2021
Phenotype-tissue expression and exploration (PTEE) resource facilitates the choice of tissue for RNA-seq-based clinical genetics studiesAkhil Velluva, Maximillian Radtke, Susanne Horn, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 4, 2017
Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profilesKlaus G Griewank, Thomas Wiesner, Rajmohan Murali, et al.
Oncotarget|April 6, 2017
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIoana Cosgarea, Selma Ugurel, Antje Sucker, et al.
Cancer Research|June 5, 2016
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic LatencyFang Zhao, Antje Sucker, Susanne Horn, et al.
Clinical and Translational Medicine|November 2, 2022
Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotypeLea Jessica Albrecht, Anna Höwner, Klaus Griewank, et al.
Clinical and Translational Medicine|January 15, 2025
RECQL4 affects MHC class II-mediated signalling and favours an immune-evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanomaSara Egea-Rodriguez, Renáta Váraljai, Thierry M Nordmann, et al.
Pageof 8